SLC5A2
SLC5A2 SGLT2 — the molecular target that 1 compounds in the wiki act on.
In one line: The kidney's sugar-reabsorbing gate — blocking it makes you pee out excess sugar.
SLC5A2 (SGLT2) is a gate in your kidneys that normally reclaims sugar back into your blood. The newer diabetes drugs (empagliflozin, canagliflozin) block it, so excess sugar leaves in your urine instead. That creates a mild calorie loss and metabolic benefit, with strong evidence for protecting the heart and kidneys — and an emerging longevity signal.
Simply: it lets you pee out some of the sugar you'd otherwise store.